Search results
Results from the WOW.Com Content Network
Jakafi is a prescription medicine used to treat people with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF.
Ruxolitinib (sold under the brand names Jakafi and Jakavi among others, and as Opzelura in cream form) is a medication used for the treatment of intermediate or high-risk myelofibrosis, [6] a type of myeloproliferative neoplasm that affects the bone marrow; [11] [12] polycythemia vera, when there has been an inadequate response to or intolerance of hydroxyurea; [6] [13] and steroid-refractory ...
In November 2011, the US Food and Drug Administration (FDA) approved ruxolitinib (Jakafi) as a treatment for intermediate or high-risk myelofibrosis. [24] [25] Ruxolitinib serves as an inhibitor of JAK 1 and 2. Data from two phase III studies of ruxolitinib showed that the treatment significantly reduced spleen volume, improved symptoms of ...
This is a list of notable academic journals about nursing.. AACN Advanced Critical Care; AACN Nursing Scan in Critical Care; Advances in Neonatal Care; American Journal of Critical Care
A Janus kinase inhibitor, also known as JAK inhibitor or jakinib, [1] is a type of immune modulating medication, which inhibits the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway in lymphocytes.
Journal of Natural Science, Biology and Medicine; Journal of Nature and Science of Medicine; Journal of Neurosciences in Rural Practice; Journal of Nursing and Midwifery Sciences; Journal of Obesity and Metabolic Research; Journal of Obstetric Anaesthesia and Critical Care; Journal of Ophthalmic and Vision Research; Journal of Oral Research and ...
The Journal of the American Medical Association (JAMA), along with JAMA Network Open and eleven specialty journals, compose the JAMA Network family of journals. [1] The journals share a common website, [ 2 ] archives and other means of access (such as RSS feeds), [ 3 ] have common policies on publishing and public relations, [ 4 ] and pool ...
Jakafi is approved in the U.S. for treating acute GvHD and is considered a remedy for certain bone marrow and blood d FDA approves Incyte's treatment for chronic graft-versus-host disease Skip to ...